We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Feb 26, we issued an updated research report on Allscripts Healthcare Solutions (MDRX - Free Report) . While the company’s strong fundamentals and acquisitions are major positives, rising operating expenses and integration risks remain major concerns. The stock carries a Zacks Rank #3 (Hold).
In the fourth quarter of 2017, the provider of information technology solutions to healthcare organizations witnessed strong financial results on strength in U.S. Core Solutions and Services, which was buoyed by the Sunrise electronic health record (EHR) platform and Allscripts Revenue Cycle Management Services. Notably, revenues in the quarter increased 27% on a year-over-year basis, while earnings per share saw 28.6% growth.
The company also has strong subsidiaries like Netsmart and CarePort, which are gaining from favorable market trends. Moreover, the company’s EHR agnostic tools, including dbMotion, EPSi, FollowMyHealth and 2bPrecise, are delivering strong results. These platforms have been gaining clients quite frequently. Furthermore, the company’s alliance with Optums has been strong.
Allscripts has also been benefitting from its acquisitions. Lately, the company signed an agreement to takeover Practice Fusion with a view to drive innovation. Moreover, the company recently expanded its strategic partnership with OptimizeRx Corp., a leading provider of digital health messaging.
Allscripts’ fourth quarter has seen active expansion of international business. Notably, the company introduced Maidstone in the U.K. It continues to expand its footprint in Australia on continued sale of the Sunrise-BOSSNet EHR platform to hospitals in Western Australia. Allscripts also initiated operations in Costa Rica with its flagship Sunrise platform.
On the flip side, in the fourth quarter, the company saw a 27% year-over-year rise in operating expenses. This was primarily due to the acquisition of EIS business of McKesson and a long sales cycle which involves decision-making at different managerial levels. This increases the company’s operating expenses and might result in cancellation of orders.
Allscripts’ continued dependence on acquisitions is also likely to pose substantial integration risks. To add to the woes, the company faces stiff competition from large players like Epic and Cerner in the Healthcare Information Technology space.
Allscripts has been underperforming the industry in the past year. The stock has gained 13.2%, compared with the industry’s gain of 18.8%.
athenahealth has a projected long-term growth rate of 20.7%. The stock has returned 10% in the past three months.
Centene has a long-term growth rate of 14.4%. The stock has gained 18.9% in the last six months.
Mednax has an expected long-term growth rate of 10%. In the last six months, the stock has gained 26%.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Allscripts' (MDRX) Fundamentals Strong Amid Stiff Competition
On Feb 26, we issued an updated research report on Allscripts Healthcare Solutions (MDRX - Free Report) . While the company’s strong fundamentals and acquisitions are major positives, rising operating expenses and integration risks remain major concerns. The stock carries a Zacks Rank #3 (Hold).
In the fourth quarter of 2017, the provider of information technology solutions to healthcare organizations witnessed strong financial results on strength in U.S. Core Solutions and Services, which was buoyed by the Sunrise electronic health record (EHR) platform and Allscripts Revenue Cycle Management Services. Notably, revenues in the quarter increased 27% on a year-over-year basis, while earnings per share saw 28.6% growth.
The company also has strong subsidiaries like Netsmart and CarePort, which are gaining from favorable market trends. Moreover, the company’s EHR agnostic tools, including dbMotion, EPSi, FollowMyHealth and 2bPrecise, are delivering strong results. These platforms have been gaining clients quite frequently. Furthermore, the company’s alliance with Optums has been strong.
Allscripts has also been benefitting from its acquisitions. Lately, the company signed an agreement to takeover Practice Fusion with a view to drive innovation. Moreover, the company recently expanded its strategic partnership with OptimizeRx Corp., a leading provider of digital health messaging.
Allscripts’ fourth quarter has seen active expansion of international business. Notably, the company introduced Maidstone in the U.K. It continues to expand its footprint in Australia on continued sale of the Sunrise-BOSSNet EHR platform to hospitals in Western Australia. Allscripts also initiated operations in Costa Rica with its flagship Sunrise platform.
On the flip side, in the fourth quarter, the company saw a 27% year-over-year rise in operating expenses. This was primarily due to the acquisition of EIS business of McKesson and a long sales cycle which involves decision-making at different managerial levels. This increases the company’s operating expenses and might result in cancellation of orders.
Allscripts’ continued dependence on acquisitions is also likely to pose substantial integration risks. To add to the woes, the company faces stiff competition from large players like Epic and Cerner in the Healthcare Information Technology space.
Allscripts has been underperforming the industry in the past year. The stock has gained 13.2%, compared with the industry’s gain of 18.8%.
Key Picks
A few better-ranked stocks in the broader medical space are athenahealth, Inc. , Centene Corporation (CNC - Free Report) and Mednax, Inc. (MD - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
athenahealth has a projected long-term growth rate of 20.7%. The stock has returned 10% in the past three months.
Centene has a long-term growth rate of 14.4%. The stock has gained 18.9% in the last six months.
Mednax has an expected long-term growth rate of 10%. In the last six months, the stock has gained 26%.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>